Biomarin Pharmaceutical Inc

Research Biomarin Pharmaceutical Inc (BMRN) on Bullrun: valuation model: 27.5% overvalued, market cap USD 11.15B, P/E 42.1. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBMRN
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal27.5% overvalued
• Market capUSD 11.15B
• P/E42.1
• Financial periodFY2025
• RevenueUSD 3.22B
• Revenue growth12.9%
• Net incomeUSD 348.90M
• Free cash flowUSD 724.96M
• Gross margin77.7%

Valuation Snapshot

Bullrun's latest valuation model marks Biomarin Pharmaceutical Inc as 27.5% overvalued; latest market cap is USD 11.15B; P/E is 42.1.

About Biomarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder;

Frequently asked questions

Is Biomarin Pharmaceutical Inc overvalued or undervalued?

Bullrun's valuation model currently marks Biomarin Pharmaceutical Inc as 27.5% overvalued.

What is Biomarin Pharmaceutical Inc's market cap?

Biomarin Pharmaceutical Inc's market capitalization is USD 11.15B.

What is Biomarin Pharmaceutical Inc's P/E ratio?

Biomarin Pharmaceutical Inc's price-to-earnings (P/E) ratio is 42.1.

What does Biomarin Pharmaceutical Inc do?

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.